CARLOS
SOLANO VERCET
CATEDRÁTICO/A DE UNIVERSIDAD
![Foto de Jose Luis](/img/nophoto.png)
Jose Luis
Piñana Sánchez
Publikationen, an denen er mitarbeitet Jose Luis Piñana Sánchez (91)
2024
-
Are any specific respiratory viruses more severe than others in recipients of allogeneic stem cell transplantation? A focus on lower respiratory tract disease
Bone Marrow Transplantation
-
EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome
Clinical Neurophysiology, Vol. 163, pp. 132-142
-
Letermovir use may impact on the Cytomegalovirus DNA fragmentation profile in plasma from allogeneic hematopoietic stem cell transplant recipients
Journal of Medical Virology, Vol. 96, Núm. 3
-
Outcome of Human Parainfluenza Virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy
Infection
-
Performance of the Roche Elecsys® IGRA SARS-CoV-2 test for the detection and quantification of virus-reactive T cells in COVID-19-vaccinated immunosuppressed patients and healthy subjects
European Journal of Clinical Microbiology and Infectious Diseases
-
Torque Teno Virus DNA Load in Blood as an Immune Status Biomarker in Adult Hematological Patients: The State of the Art and Future Prospects
Viruses, Vol. 16, Núm. 3
-
Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy
Bone Marrow Transplantation, Vol. 59, Núm. 1, pp. 93-100
-
Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation
Journal of Infectious Diseases, Vol. 229, Núm. 1, pp. 83-94
2023
-
Cytomegalovirus DNAemia in haematological patients undergoing CD19-directed chimeric antigen receptor T-cell therapy: should it be systematically monitored?
Clinical Microbiology and Infection
-
Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir
Transplant Infectious Disease, Vol. 25, Núm. 2
-
Immunovirology of cytomegalovirus infection in allogeneic stem cell transplant recipients undergoing prophylaxis with letermovir: A narrative review
Journal of Medical Virology, Vol. 95, Núm. 8
-
Impact of cytomegalovirus immunodominant HLA-I donor–recipient matching on the incidence and features of virus DNAemia and virus-specific T-cell immune reconstitution in unmanipulated haploidentical hematopoietic stem cell transplantation
Transplant Infectious Disease, Vol. 25, Núm. 3
-
Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry
Frontiers in Immunology, Vol. 14
-
In vitro assessment of the combined effect of letermovir and sirolimus on cytomegalovirus replication
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 36, Núm. 5, pp. 526-530
-
Monitoring of plasma Torque teno virus, total Anelloviridae and Human Pegivirus 1 viral load for the prediction of infectious events and acute graft versus host disease in the allogeneic hematopoietic stem cell transplantation setting
Journal of Medical Virology, Vol. 95, Núm. 9
-
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
Blood Cancer Journal, Vol. 13, Núm. 1
-
Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients
Viruses, Vol. 15, Núm. 10
-
Respiratory virus infections after allogeneic stem cell transplantation: Current understanding, knowledge gaps, and recent advances
Transplant Infectious Disease, Vol. 25, Núm. S1
-
SARS-CoV-2 Immunity in Hematopoietic Stem Cell Transplant and Cell Therapy Recipients: What Do We Know, and What Remains to Be Determined?
Hemato, Vol. 4, Núm. 2, pp. 170-183
-
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination
Bone Marrow Transplantation, Vol. 58, Núm. 5, pp. 567-580